HK1118579A1 - Adamts13-comprising compositions having thrombolytic activity - Google Patents

Adamts13-comprising compositions having thrombolytic activity

Info

Publication number
HK1118579A1
HK1118579A1 HK08109912.8A HK08109912A HK1118579A1 HK 1118579 A1 HK1118579 A1 HK 1118579A1 HK 08109912 A HK08109912 A HK 08109912A HK 1118579 A1 HK1118579 A1 HK 1118579A1
Authority
HK
Hong Kong
Prior art keywords
adamts13
thrombus
compositions
thrombolytic activity
disintegrating
Prior art date
Application number
HK08109912.8A
Other languages
English (en)
Inventor
Denisa Wagner
Anil Kumar Chauhan
Friedrich Scheiflinger
Barbara Plaimauer
Original Assignee
Baxter Int
Baxter Healthcare Sa
Cbr Inst For Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa, Cbr Inst For Biomedical Res filed Critical Baxter Int
Publication of HK1118579A1 publication Critical patent/HK1118579A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK08109912.8A 2005-06-17 2008-09-05 Adamts13-comprising compositions having thrombolytic activity HK1118579A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69192705P 2005-06-17 2005-06-17
US72932305P 2005-10-21 2005-10-21
US77126506P 2006-02-07 2006-02-07
PCT/EP2006/005800 WO2006133955A1 (en) 2005-06-17 2006-06-16 Adamts13-comprising compositions having thrombolytic activity

Publications (1)

Publication Number Publication Date
HK1118579A1 true HK1118579A1 (en) 2009-02-13

Family

ID=36956096

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08109912.8A HK1118579A1 (en) 2005-06-17 2008-09-05 Adamts13-comprising compositions having thrombolytic activity

Country Status (10)

Country Link
US (4) US20070015703A1 (xx)
EP (1) EP1902141B1 (xx)
AT (1) ATE544866T1 (xx)
AU (1) AU2006257073B2 (xx)
CA (1) CA2606351C (xx)
DK (1) DK1902141T3 (xx)
ES (1) ES2382104T3 (xx)
HK (1) HK1118579A1 (xx)
PL (1) PL1902141T3 (xx)
WO (1) WO2006133955A1 (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1902141B1 (en) 2005-06-17 2012-02-08 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
FR2918375B1 (fr) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
US20090317375A1 (en) * 2008-05-12 2009-12-24 Immune Disease Institute, Inc. Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
EP3495488A1 (en) * 2008-10-27 2019-06-12 Baxalta GmbH Models of thrombotic thrombocytopenic purpura and methods of use thereof
ES2685503T3 (es) 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
JP5411582B2 (ja) * 2009-06-02 2014-02-12 一般財団法人化学及血清療法研究所 Ａｄａｍｔｓ１３による細胞移植増強補助剤
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
JP5819303B2 (ja) 2009-09-21 2015-11-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 安定化された液体および凍結乾燥ａｄａｍｔｓ１３製剤
MX344322B (es) * 2009-10-16 2016-12-13 Omeros Corp Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento.
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ746139A (en) * 2011-04-08 2023-11-24 Omeros Corp Methods for treating conditions associated with masp-2 dependent complement activation
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
CN105991563B (zh) * 2015-02-05 2020-07-03 阿里巴巴集团控股有限公司 一种保护敏感数据安全的方法、装置及三方服务系统
US10639307B2 (en) * 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN109312343B (zh) 2015-12-14 2022-09-27 冷泉港实验室 用于治疗常染色体显性精神发育迟滞5型和Dravet综合征的反义寡聚体
EP3401685B1 (en) 2016-01-08 2021-12-01 Kyoto University Diagnostic method and medicine comprising adamts13 as main ingredient
MX2019001255A (es) * 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
RS65031B1 (sr) 2017-08-25 2024-02-29 Stoke Therapeutics Inc Antisens oligomeri za lečenje stanja i bolesti
WO2021067668A1 (en) * 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
AU2021248679A1 (en) 2020-04-02 2022-10-27 Takeda Pharmaceutical Company Limited ADAMTS13 variant, compositions, and uses thereof
WO2021231107A1 (en) 2020-05-11 2021-11-18 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
WO2021234458A1 (en) 2020-05-22 2021-11-25 Takeda Pharmaceutical Company Limited Adamts13 compositions and methods for treating and diagnosing complications of coronavirus disease
MX2023005661A (es) * 2020-11-18 2023-05-26 Green Cross Corp Variante de adamts13 que tiene actividad o velocidad de escape incrementada contra un autoanticuerpo.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082218A (xx) * 1973-11-10 1975-07-03
US4791138A (en) * 1983-12-14 1988-12-13 The Upjohn Company Method for treating or preventing deep vein thrombosis using lipoxygenase inhibitors
JP4944324B2 (ja) * 1999-07-13 2012-05-30 ボルダー バイオテクノロジー， インコーポレイテッド 免疫グロブリン融合タンパク質
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes
US20030073115A1 (en) * 2002-09-16 2003-04-17 Shyam Ramakrishnan Regulation of human galanin receptor-like g protein coupled receptor
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
EP1902141B1 (en) 2005-06-17 2012-02-08 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity

Also Published As

Publication number Publication date
US20070015703A1 (en) 2007-01-18
EP1902141A1 (en) 2008-03-26
US10233436B2 (en) 2019-03-19
CA2606351A1 (en) 2006-12-21
DK1902141T3 (da) 2012-05-07
EP1902141B1 (en) 2012-02-08
US20190161746A1 (en) 2019-05-30
US11124787B2 (en) 2021-09-21
WO2006133955A8 (en) 2007-11-29
CA2606351C (en) 2016-12-13
WO2006133955A1 (en) 2006-12-21
AU2006257073B2 (en) 2011-08-04
ATE544866T1 (de) 2012-02-15
PL1902141T3 (pl) 2012-12-31
ES2382104T3 (es) 2012-06-05
US20130136732A1 (en) 2013-05-30
US20220002703A1 (en) 2022-01-06
AU2006257073A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
HK1118579A1 (en) Adamts13-comprising compositions having thrombolytic activity
MX2012004551A (es) Nuevas composiciones para prevenir y/o tratar trastornos de almacenamiento lisosomal.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
MX2009005527A (es) Metodos para el tratamiento de hipercolesterolemia.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
TW200637522A (en) Skin treatment articles and methods
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2008017025A3 (en) Combination therapy
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
MXPA05011858A (es) Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico.
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2007041388A3 (en) Prevention and treatment of hearing disorders
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
BR0111785A (pt) Composições e métodos para tratamento de candidìase